Toronto is bracing for the potential closure of vital harm reduction services as the Ontario government moves to finish funding for all supervised consumption sites (SCS) across the province. The decision, announced Friday and confirmed by multiple advocacy groups, will impact access to life-saving resources for people who use drugs, particularly as the illicit drug supply becomes increasingly toxic.
The move will result in more deaths, advocates warn, at a time when the city is seeing an increasingly tainted drug supply. Specifically, the Moss Park Overdose Prevention Site and the site at Fred Victor on Queen Street East are slated to lose their provincial funding as of June 13, 2026, unless alternative funding sources are secured. This decision reflects a shift in the province’s approach, prioritizing treatment and recovery over harm reduction strategies.
Impact on Toronto’s Harm Reduction Services
Keith Hambly, CEO of Fred Victor, expressed deep disappointment with the government’s decision, stating the organization was “deeply disappointed” by the decision. He emphasized that these services are “a critical part of a compassionate and evidence-based response to the ongoing overdose crisis.” The Fred Victor Centre and South Riverdale Community Health Centre are the last two provincially funded sites in Toronto. Staff and clients at the South Riverdale location are “understandably devastated” by the news, according to a spokesperson.
The province, in a letter to site directors, stated the decision “reflects Ontario’s commitment to prioritizing treatment, recovery and supports that facilitate individuals move toward long-term stability while protecting Ontario communities.” The letter likewise requested a wind-down plan by April 10, 2026 and strategies for transitioning clients to other community-based treatment and recovery supports.
Growing Concerns Over Tainted Drug Supply
The timing of this funding cut is particularly concerning given the escalating crisis surrounding the presence of medetomidine, a veterinary tranquilizer, in the illicit drug supply. This substance, which has caused harm in the United States, is contributing to increasingly severe withdrawal symptoms and a rise in overdoses in Toronto. The veterinary tranquilizer medetomidine has caused harm in the U.S. And is tied to the latest treacherous twist in the city’s drug-poisoning crisis.
Harm reduction advocates argue that supervised consumption sites are essential for mitigating the risks associated with a contaminated drug supply. These sites provide a safe environment for people to use pre-obtained drugs under the supervision of trained staff, reducing the risk of overdose and providing access to medical care and support services.
Province Prioritizes Treatment and Recovery
The Ford government’s decision aligns with its stated commitment to prioritizing treatment and recovery-focused approaches to the opioid crisis. However, critics argue that cutting funding for harm reduction services will undermine efforts to save lives and connect people with the treatment they necessitate. The move follows a pattern of the province reducing support for supervised consumption sites, citing concerns from local residents.
The decision to end funding impacts all supervised consumption sites in Ontario, not just those in Toronto. This province-wide shift in policy raises questions about the future of harm reduction services and the government’s overall strategy for addressing the ongoing opioid crisis.
What comes next for Toronto’s harm reduction landscape remains uncertain. Advocacy groups are scrambling to identify alternative funding sources and explore options for keeping the affected sites open. The coming months will be critical in determining the long-term impact of this decision on the health and well-being of people who use drugs in the city.
Share your thoughts on this important issue in the comments below.
